Shots:
- Haisco Pharma entered an exclusive licensing deal with AbbVie, granting later global rights (ex-China, Hong Kong & Macau) to develop, manufacture & commercialize novel pain therapies
- As per the deal, Haisco will receive $30M upfront, with the potential to receive up to $715M in development, regulatory, and commercial milestones, along with tiered royalties on future net sales
- The collaboration expands Haisco’s pipeline and international scope, involving multiple pain-related compounds in China across stages from preclinical to P-I, with AbbVie supporting development and commercialization activities
Ref: PRNewswire | Image: Haisco and AbbVie | Press Release
Related News: AbbVie Reports Topline P-III (EPCORE DLBCL-1) Trial Data on Epcoritamab for R/R Diffuse Large B-cell Lymphoma (DLBCL)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
